Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
Related Posts
Second Annual MCT Meeting in Tunisia on October 8th & 9th :
News / October 9, 2015
MCT attended the 2019 Clinical Research Forum organized by the UAE MOH
News / December 13, 2019

